AimedBio Signs Strategic Investment in AI Drug Discovery Company Galux
2026.05.27
- AimedBio has signed a strategic investment and joint research agreement with Galux.
- AimedBio will make a strategic investment in Galux, establishing a long-term collaboration framework.
- The two companies will jointly develop next-generation therapeutics by combining ADC technology and AI-driven protein design.
- A key focus of the collaboration is the development of a blood–brain barrier (BBB)–penetrating protein delivery platform.
- Galux will utilize its AI protein design platform, GaluxDesign, while AimedBio will contribute its expertise in ADC development and antibody discovery.
- The partnership aims to address a major challenge in neuroscience drug development: efficient delivery across the BBB.
